Company Analysis

Ultragenyx Pharmaceutical Inc. (RARE)

Nasdaq: RARE · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 2011
Grade5.9
◀ Past 7.5● Present 5.9▶ Future 4.5
1 est.

Who runs Ultragenyx Pharmaceutical Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kakkis Emil D
President & CEO. First filing Jan 2014, latest Apr 20, 2026, 26 filings in all.
Officers reporting now
8
of 15 people with a filing in the last fifteen months
Directors reporting now
7
25 people on the record since 2014
Officerssales are open-market, Oct 19, 2025 to Oct 19, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Horn HowardChief Financial OfficerOct 2023Oct 19, 202612 · $1.2M
Huizenga Theodore AlanSVP, Chief Accounting OfficerMar 2014Sep 15, 20264 · $100,000
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 2016Aug 4, 20265 · $500,000
Crombez EricEVP and Chief Medical OfficerMay 2023May 6, 20262 · $200,000
Kakkis Emil DPresident & CEOJan 2014Apr 20, 20261 · $1.2M
Harris ErikEVP & Chief Commercial OfficerJun 2019Apr 20, 20261 · $200,000
Huang Dennis KarlEVP, Chief Technical Operations OfficerMay 2015Apr 20, 2026none
Pinion John RichardEVP, Chief Quality Operations OfficerJul 2015Apr 20, 20261 · $200,000
Directorssales are open-market, Oct 19, 2025 to Oct 19, 2026
NameRoleFirst filingLatest filingSales, 12 months
Sanders Corazon (Corsee) D.directorJun 2021Jun 15, 20261 · $100,000
Dunsire DeborahdirectorApr 2017May 18, 2026none
Fust Matthew KdirectorJan 2014May 18, 2026none
Narachi MichaeldirectorFeb 2015May 18, 2026none
Ray AmritdirectorApr 2022May 18, 2026none
Suliman ShehnaazdirectorFeb 2019May 18, 20261 · $100,000
Welch Daniel GdirectorApr 2015May 18, 2026none
Earlier names on the record10, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RARE · research, not advice